880 related articles for article (PubMed ID: 12468336)
1. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
2. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
3. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study.
Kim HS; Kim TJ; Chung HH; Kim JW; Kim BG; Park NH; Song YS; Bae DS; Kang SB
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1513-20. PubMed ID: 19449027
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.
Matsuo K; Eno ML; Im DD; Rosenshein NB; Sood AK
Gynecol Oncol; 2010 Jan; 116(1):61-5. PubMed ID: 19840886
[TBL] [Abstract][Full Text] [Related]
5. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
7. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
9. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
11. Extreme drug resistance is common after prior exposure to paclitaxel.
Geisler JP; Linnemeier GC; Thomas AJ; Manahan KJ
Gynecol Oncol; 2007 Sep; 106(3):538-40. PubMed ID: 17561236
[TBL] [Abstract][Full Text] [Related]
12. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
13. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
Marth C; Tropé C; Vergote IB; Kristensen GB
Eur J Cancer; 1998 Jul; 34(8):1175-80. PubMed ID: 9849475
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
15. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer.
Pant AC; Diaz-Montes T; Tanner E; Ahmad S; Giuntoli RL; Holloway RW; Bristow RE
J Chemother; 2010 Aug; 22(4):270-4. PubMed ID: 20685633
[TBL] [Abstract][Full Text] [Related]
16. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
Dittrich Ch; Sevelda P; Salzer H; Obermair A; Speiser P; Breitenecker G; Schemper M; Kaider A;
Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113
[TBL] [Abstract][Full Text] [Related]
17. Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma.
Eltabbakh GH
J Surg Oncol; 2000 Mar; 73(3):148-52. PubMed ID: 10738268
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.
Mehta RS; Bornstein R; Yu IR; Parker RJ; McLaren CE; Nguyen KP; Li KT; Fruehauf JP
Breast Cancer Res Treat; 2001 Apr; 66(3):225-37. PubMed ID: 11510694
[TBL] [Abstract][Full Text] [Related]
19. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
20. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
